N. Yamamoto

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel (2009)

Sekine, I., Ichinose, Y., Nishiwaki, Y., Yamamoto, N., Tsuboi, M., Nakagawa, K., ...

Background: This report describes quality of life (QoL) findings of a randomized study comparing gefitinib with docetaxel in patients with advanced/metastatic pretreated non-small-cell lung cancer....

Carbon-ion radiotherapy: clinical aspects and related dosimetry (2009)

Fukumura, A., Tsujii, H., Kamada, T., Baba, M., Tsuji, H., Kato, H., ...

The features of relativistic carbon-ion beams are attractive from the viewpoint of radiotherapy. They exhibit not only a superior physical dose distribution but also an increase in biological...

P.2. Syncope, Pacemaker, CRT & ICD: P.2.7 Pacemaker Registry in Saitama Prefecture, Japan (2005)

Suga, C., Matsumoto, K., Kato, R., Kurita, A., Katsumoto, K., Endo, Y., ...

Objective Pacemaker Registry has been started since 2004 to establish a reliable source of pacemaker use in Saitama-prefecture having the fifth largest population in Japan. Method Patient...

Contrast analysis of dislocation images in TEM-cathodoluminescence technique (2005)

Nakaji, D., Grillo, V., Yamamoto, N., Mukai, T.

Monochromatic cathodoluminescence CL images of the threading dislocations in Si-doped n-GaN were observed by the TEM–CL technique. We studied dependence of the contrast and the FWHM of the...

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors (2003)

Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., ...

Background: This phase I dose-escalating study investigated the tolerability and toxicity of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839)...

Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs (2002)

Sekine, I., Yamamoto, N., Kunitoh, H., Ohe, Y., Tamura, T., Kodama, T., ...

Background: Although the evaluation of new investigational drugs in phase I, II and III trials requires considerable time and patient resources, only a few of these drugs are ultimately established...

Anti-HIV Activity of Sulfonated Arabinofuranan and Xylofuranan (2001)

T. Yoshida, B. W. Kang, K. Hattori, T. Miura, Y. Kaneko, H. Nakashima, ...

Structural requirement for the two-step dimerization of human immunodeficiency virus type 1 genome (2000)

Takahashi, K. I., Baba, S., Chattopadhyay, P., Koyanagi, Y., Yamamoto, N., Takaku, H., ...

Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey (1999)

Yamakawa-Kobayashi, K, Yanagi, H, Fukayama, H, Hirano, C, Shimakura, Y, Yamamoto, N, ...

Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology Group (1998)

Kasai, T, Ohe, Y, Nishio, K, Kunitoh, H, Tamura, T, Sekine, I, ...

Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment (1998)

Yamamoto, N, Katsumata, N, Watanabe, T, Omuro, Y, Ando, M, Narabayashi, M, ...

A method for analyzing the qualitative and quantitative aspects of gene expression: a transcriptional profile revealed for HeLa cells (1998)

Ryo, A, Kondoh, N, Wakatsuki, T, Hada, A, Yamamoto, N, Yamamoto, M

Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status (1996)

Sakuragi, T, Oshita, F, Nagashima, S, Kasai, T, Kurata, T, Fukuda, M, ...

A New Mutant Rat With Turning Behavior (Tur) (1995)

Yamazaki, K., Mikami, T., Kawaguchi, A., Kuwabara, M., Nozaki, Y., Hosokawa, S., ...

A New Mutant Rat With Hyperbilirubinuria (hyb) (1995)

Yamazaki, K., Mikami, T., Hosokawa, S., Tagaya, O., Nozaki, Y., Kawaguchi, A., ...

Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results (1995)

Oshita, F, Kasai, T, Kurata, T, Fukuda, M, Yamamoto, N, Ohe, Y, ...

Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335 (1992)

Pauwels, R, Reymen, D, Yamamoto, N, ...

The drug Ro5-3335 [7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2(H)-one] inhibits human immunodeficiency virus type 1 (HIV-1) gene expression at the transcriptional level through interference with...

Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus (1992)

De Vreese, K, Pauwels, R, Yamamoto, N, ...

Recently, several classes of compounds have been shown to be extremely selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in vitro. These include the...

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event (1992)

Yamamoto, N, Pauwels, R, Baba, M, Nakashima, H, ...

A series of bicyclams have been shown to be potent and selective inhibitors of human immunodeficiency virus (HIV). The compounds are inhibitory to the replication of various HIV-1 and HIV-2 strains...

12-0-tetradecanoylphorbol 13-acetat-induclible proteins are synthesized at an increased rate in Bloom syndrome fibroblasts. (1983)

Mallick, U., Rahmsdorf, H.J., Yamamoto, N., Ponta, H., Wegner, R.D., Herrlich, P.

Proceedings of the National Academy of Sciences of the United States of America, 79(1982) S.7886-90

TPA-inducible proteins are synthesized at elevated rate in Bloom's syndrome. (1981)

Mallick, U., Rahmsdorf, H.J., Yamamoto, N., Ponta, H., Herrlich, P.

Meeting of the Internat.Soc.of Developmental Biologists, Basel, CH, August 28 - September 1, 1981

Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours.

Oki, E., Sakaguchi, Y., Toh, Y., Oda, S., Maehara, Y., Yamamoto, N., ...

Various types of anti-neoplastic agents induce apoptosis in vitro, but less is known of the role of this mode of cell death in tumours treated in vivo. We examined the induction of apoptosis by oral...

Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer.

Korbelik, M., Naraparaju, V. R., Yamamoto, N.

The effect of Photofrin-based photodynamic therapy (PDT) and adjuvant treatment with serum vitamin D3-binding protein-derived macrophage-activating factor (DBPMAF) was examined using a mouse SCCVII...

The value of serum alpha-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy.

Korbelik, M., Naraparaju, V. R., Yamamoto, N.

Serum activity of alpha-N-acetylgalactosaminidase (NaGalase), the extracellular matrix-degrading enzyme that appears to be produced exclusively by cancer cells, was measured in mice bearing SCCVII...

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.

Ando, M., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., Yamamoto, N., ...

We conducted a phase I study of irinotecan (CPT-11) and etoposide (VP-16) given sequentially to untreated patients with metastatic non-small-cell lung cancer. Arm A: CPT-11 was given over 90 min on...

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

Nakagawa, K, Kudoh, S, Matsui, K, Negoro, S, Yamamoto, N, Latz, J E, ...

The purpose of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of pemetrexed with folate and vitamin B12 supplementation (FA/VB12) in Japanese patients with...

Analysis of the ANA gene as a candidate for the chromosome 21q oral cancer susceptibility locus

Yamamoto, N, Uzawa, K, Yakushiji, T, Shibahara, T, Noma, H, Tanzawa, H

Loss of heterozygosity (LOH) on the long arm of chromosome 21 (21q) is observed in several human malignancies. We identified novel tumour suppressor loci on this region in primary oral squamous cell...

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer

Yamada, M, Kudoh, S, Fukuda, H, Nakagawa, K, Yamamoto, N, Nishimura, Y, ...

Dose-escalation study was performed to evaluate the maximum tolerated dose, recommended dose and toxicity profile of weekly irinotecan with daily carboplatin and concurrent thoracic radiotherapy in...

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer

Goto, K, Sekine, I, Nishiwaki, Y, Kakinuma, R, Kubota, K, Matsumoto, T, ...

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)

Yamamoto, N, Fukuoka, M, Negoro, S-I, Nakagawa, K, Saito, H, Matsui, K, ...

Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer

Kurata, T, Tamura, K, Yamamoto, N, Nogami, T, Satoh, T, Kaneda, H, ...

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

Sekine, I, Nokihara, H, Horiike, A, Yamamoto, N, Kunitoh, H, Ohe, Y, ...